Xenocor Closes $10M Series A Financing

Xenocor announces a $10 million Series A funding led by GenHenn Venture Fund I with participation from Baranco Investments, Inc., Barvest Ventures, Inc. and Patel Family Investments. Michael J. Hennessy Jr., GenHenn Capital will join the Xenocor board of directors.

The funds will be used for the 2023 launch of the Saberscope and to continue executing on its robust innovation roadmap.

“Xenocor is laser focused on facilitating the evolution of the 35-year-old laparoscopic visualization model to something that clearly better serves care givers and patients during minimally invasive surgery,” shared Charles DeCoster IV, CEO of Xenocor. “Our FDA cleared Saberscope improves visualization, dramatically diminishes workflow complexity, increases safety and reduces waste.”

With an addressable market of $4.5 billion in the U.S. alone, Xenocor has created the best technology on a scalable platform, hired the right veteran medical device leadership and is following the right strategic course to capture meaningful share of this dynamic market.

“We are beyond thrilled to be leading the Xenocor Series A. Based on the deep insights I have gathered during my long career in healthcare leadership, I believe Xenocor will have a transformational impact on minimally invasive surgery,” shared Michael J. Hennessy Jr., GenHenn managing partner. “Their unique technology coupled with their veteran leadership will change the future of laparoscopy forever.”